JP6290187B2 - 癌の処置のためのタンパク質の部位特異的標識及び標的送達 - Google Patents

癌の処置のためのタンパク質の部位特異的標識及び標的送達 Download PDF

Info

Publication number
JP6290187B2
JP6290187B2 JP2015511804A JP2015511804A JP6290187B2 JP 6290187 B2 JP6290187 B2 JP 6290187B2 JP 2015511804 A JP2015511804 A JP 2015511804A JP 2015511804 A JP2015511804 A JP 2015511804A JP 6290187 B2 JP6290187 B2 JP 6290187B2
Authority
JP
Japan
Prior art keywords
protein
annexin
pharmaceutical composition
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015511804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519339A (ja
JP2015519339A5 (enExample
Inventor
クランツ，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015519339A publication Critical patent/JP2015519339A/ja
Publication of JP2015519339A5 publication Critical patent/JP2015519339A5/ja
Application granted granted Critical
Publication of JP6290187B2 publication Critical patent/JP6290187B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015511804A 2012-05-11 2013-05-13 癌の処置のためのタンパク質の部位特異的標識及び標的送達 Expired - Fee Related JP6290187B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261688308P 2012-05-11 2012-05-11
US61/688,308 2012-05-11
US201261741984P 2012-08-01 2012-08-01
US61/741,984 2012-08-01
US201361848601P 2013-01-07 2013-01-07
US61/848,601 2013-01-07
US201361849034P 2013-01-17 2013-01-17
US61/849,034 2013-01-17
PCT/US2013/040823 WO2013170272A2 (en) 2012-05-11 2013-05-13 Site-specific labeling and targeted delivery of proteins for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2015519339A JP2015519339A (ja) 2015-07-09
JP2015519339A5 JP2015519339A5 (enExample) 2016-07-07
JP6290187B2 true JP6290187B2 (ja) 2018-03-07

Family

ID=49551481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511804A Expired - Fee Related JP6290187B2 (ja) 2012-05-11 2013-05-13 癌の処置のためのタンパク質の部位特異的標識及び標的送達

Country Status (5)

Country Link
US (1) US9545449B2 (enExample)
EP (1) EP2850201A4 (enExample)
JP (1) JP6290187B2 (enExample)
CA (1) CA2873112A1 (enExample)
WO (1) WO2013170272A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5829793B2 (ja) 2007-03-14 2015-12-09 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 結合性リガンドが結合したツブリシンの薬剤送達結合体
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2908818A4 (en) 2012-10-16 2016-07-13 Endocyte Inc CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
KR102538993B1 (ko) 2013-10-15 2023-06-02 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
BR112016028835A2 (pt) 2014-06-13 2017-10-24 Novartis Ag derivados de auristatina e conjugados dos mesmos
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
CN108135881B (zh) * 2015-08-11 2020-11-13 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
JP2020518240A (ja) * 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
US20220249676A1 (en) * 2019-06-05 2022-08-11 Boston Scientific Scimed, Inc. Click chemistry capturable platinum-based antineoplastic agents
KR20240041379A (ko) * 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Il-2에 접합된 체크포인트 억제제 및 이의 용도
US20230201365A1 (en) * 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
CA2292724A1 (en) 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US20020164649A1 (en) 2000-10-25 2002-11-07 Rajendra Singh Mass tags for quantitative analysis
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
AU2003228449A1 (en) 2002-04-04 2003-10-27 California Institute Of Technology Directed protein docking algorithm
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US8030459B2 (en) 2002-07-19 2011-10-04 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
CN100577686C (zh) 2004-06-18 2010-01-06 Ipf医药有限公司 寡聚肽及其治疗hiv感染的用途
US8946391B2 (en) 2006-03-24 2015-02-03 The Regents Of The University Of California Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
EP2306986B1 (en) * 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2350112A4 (en) * 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Site specific N-termin protein modifications and conjugate formation
US8658768B2 (en) 2009-06-03 2014-02-25 Mosamedix B.V. Method for enhancing phagocytosis of phosphatidylserine-exposing cells
CA2790343A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
CN103025164B (zh) * 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
US9770515B2 (en) 2010-06-01 2017-09-26 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives

Also Published As

Publication number Publication date
US20150202314A1 (en) 2015-07-23
JP2015519339A (ja) 2015-07-09
EP2850201A4 (en) 2016-08-31
WO2013170272A2 (en) 2013-11-14
CA2873112A1 (en) 2013-11-14
US9545449B2 (en) 2017-01-17
EP2850201A2 (en) 2015-03-25
WO2013170272A3 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
JP6290187B2 (ja) 癌の処置のためのタンパク質の部位特異的標識及び標的送達
Rahimizadeh et al. Albumin: an emerging opportunity in drug delivery
JP7490735B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
JP6355563B2 (ja) Ｘｔｅｎ共役組成物およびそれを製造する方法
US10894813B2 (en) Methods of using therapeutic p53 peptides
CN105934257B (zh) 用于含氮和羟基的药物的生物可逆引入基团
JP6426103B2 (ja) ｃ−Ｍｅｔタンパク質アゴニスト
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP6657464B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
CN117567535A (zh) 生物正交组合物
JP2009520040A (ja) 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
HK1211205A1 (en) Orally Bioavailable Lipid-based Constructs
JP2011184442A (ja) Ｉｌ−２１の誘導体
CN102245636A (zh) 用于药物递送的依托泊苷和多柔比星结合物
JP2005508332A (ja) 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
TW202500573A (zh) 細胞穿透肽序列
Lim Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic
JP2024512775A (ja) 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
WO2023077126A1 (en) Trans-cyclooctene conjugates
JPH03505576A (ja) 有機化合物に関する改良
JP2021521270A (ja) 治療剤の制御放出用組成物
WO2017212494A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2018183232A2 (en) Peptides and methods for targeted delivery to tumors
US20250049936A1 (en) Bioorthogonal compositions
WO2024229427A1 (en) Tetrazine-based targeting agents for in vivo delivery of a payload

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180207

R150 Certificate of patent or registration of utility model

Ref document number: 6290187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees